123 related articles for article (PubMed ID: 10405512)
21. Pervasive developmental disorders not otherwise specified. A developmental-psychopathological approach for the development of made-to-measure treatment planning.
Verheij F; van Loon H
Acta Paedopsychiatr; 1992; 55(4):235-42. PubMed ID: 1492555
[TBL] [Abstract][Full Text] [Related]
22. [Review of psychopharmacological treatments in adolescents and adults with autistic disorders].
Baghdadli A; Gonnier V; Aussilloux C
Encephale; 2002; 28(3 Pt 1):248-54. PubMed ID: 12091786
[TBL] [Abstract][Full Text] [Related]
23. Etiologic yield of autistic spectrum disorders: a prospective study.
Battaglia A; Carey JC
Am J Med Genet C Semin Med Genet; 2006 Feb; 142C(1):3-7. PubMed ID: 16419094
[TBL] [Abstract][Full Text] [Related]
24. Distinct patterns of grey matter abnormality in high-functioning autism and Asperger's syndrome.
McAlonan GM; Suckling J; Wong N; Cheung V; Lienenkaemper N; Cheung C; Chua SE
J Child Psychol Psychiatry; 2008 Dec; 49(12):1287-95. PubMed ID: 18673405
[TBL] [Abstract][Full Text] [Related]
25. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability.
Chez MG; Burton Q; Dowling T; Chang M; Khanna P; Kramer C
J Child Neurol; 2007 May; 22(5):574-9. PubMed ID: 17690064
[TBL] [Abstract][Full Text] [Related]
26. Emotional distress and its correlates among parents of children with pervasive developmental disorders.
Yamada A; Suzuki M; Kato M; Suzuki M; Tanaka S; Shindo T; Taketani K; Akechi T; Furukawa TA
Psychiatry Clin Neurosci; 2007 Dec; 61(6):651-7. PubMed ID: 18081627
[TBL] [Abstract][Full Text] [Related]
27. Differences in finger length ratio between males with autism, pervasive developmental disorder-not otherwise specified, ADHD, and anxiety disorders.
de Bruin EI; Verheij F; Wiegman T; Ferdinand RF
Dev Med Child Neurol; 2006 Dec; 48(12):962-5. PubMed ID: 17109783
[TBL] [Abstract][Full Text] [Related]
28. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.
Posey DJ; Aman MG; McCracken JT; Scahill L; Tierney E; Arnold LE; Vitiello B; Chuang SZ; Davies M; Ramadan Y; Witwer AN; Swiezy NB; Cronin P; Shah B; Carroll DH; Young C; Wheeler C; McDougle CJ
Biol Psychiatry; 2007 Feb; 61(4):538-44. PubMed ID: 17276750
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
Klassen AF; Miller A; Fine S
Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
[TBL] [Abstract][Full Text] [Related]
30. Psychopharmacological treatment of non-comorbid and comorbid pervasive developmental disorder and pediatric bipolar disorder.
Hamrin V; McDonnell MA; Moffett J; Durso S
Minerva Pediatr; 2008 Feb; 60(1):87-101. PubMed ID: 18277368
[TBL] [Abstract][Full Text] [Related]
31. Open trial of risperidone in 24 young children with pervasive developmental disorders.
Masi G; Cosenza A; Mucci M; Brovedani P
J Am Acad Child Adolesc Psychiatry; 2001 Oct; 40(10):1206-14. PubMed ID: 11589534
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders.
Findling RL
J Clin Psychiatry; 2005; 66 Suppl 10():26-31. PubMed ID: 16401147
[TBL] [Abstract][Full Text] [Related]
33. [Medical treatment of pervasive developmental disorders].
Fuentes J; Gallano I
Rev Neurol; 2001 Aug 1-15; 33(3):208-10. PubMed ID: 11588711
[TBL] [Abstract][Full Text] [Related]
34. [Pharmaco-therapeutic evaluation of medical treatments of adult autistics and multi-handicapped patients in a public mental health unit].
Armand-Branger S; Poisson N; Gaudoneix-Taïeb M; Ramos O
Encephale; 2009 Sep; 35(4):370-6. PubMed ID: 19748374
[TBL] [Abstract][Full Text] [Related]
35. [Prevalence of depressive disorders in children and adolescents attending primary care. A survey with the Aquitaine Sentinelle Network].
Mathet F; Martin-Guehl C; Maurice-Tison S; Bouvard MP
Encephale; 2003; 29(5):391-400. PubMed ID: 14615688
[TBL] [Abstract][Full Text] [Related]
36. [Current status of autism studies].
Kurita H
Seishin Shinkeigaku Zasshi; 2001; 103(1):64-75. PubMed ID: 11383012
[TBL] [Abstract][Full Text] [Related]
37. A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders.
Esbensen AJ; Greenberg JS; Seltzer MM; Aman MG
J Autism Dev Disord; 2009 Sep; 39(9):1339-49. PubMed ID: 19434487
[TBL] [Abstract][Full Text] [Related]
38. Overuse of psychotropic medications among children and adolescents with autism spectrum disorders: perspective from a developing country.
Memari AH; Ziaee V; Beygi S; Moshayedi P; Mirfazeli FS
Res Dev Disabil; 2012; 33(2):563-9. PubMed ID: 22119705
[TBL] [Abstract][Full Text] [Related]
39. Complementary and alternative medicine use in a large pediatric autism sample.
Perrin JM; Coury DL; Hyman SL; Cole L; Reynolds AM; Clemons T
Pediatrics; 2012 Nov; 130 Suppl 2():S77-82. PubMed ID: 23118257
[TBL] [Abstract][Full Text] [Related]
40. Prescription Trends of Psychotropics in Children and Adolescents with Autism Based on Nationwide Health Insurance Data.
Hong M; Lee SY; Han J; Park JC; Lee YJ; Hwangbo R; Chang H; Cho SW; Bhang SY; Kim B; Hwang JW; Bahn GH
J Korean Med Sci; 2017 Oct; 32(10):1687-1693. PubMed ID: 28875615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
